NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CODX Stock Alerts $1.16 +0.02 (+1.75%) (As of 11:53 AM ET) Add Compare Share Share Today's Range$1.15▼$1.1750-Day Range$1.06▼$1.2752-Week Range$0.98▼$1.89Volume11,033 shsAverage Volume63,638 shsMarket Capitalization$36.26 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Co-Diagnostics alerts: Email Address Co-Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside113.7% Upside$2.50 Price TargetShort InterestHealthy1.45% of Shares Sold ShortDividend StrengthN/ASustainability-1.10Upright™ Environmental ScoreNews Sentiment0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector291st out of 908 stocksSurgical & Medical Instruments Industry37th out of 97 stocks 3.0 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.45% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Co-Diagnostics has recently decreased by 8.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCo-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Co-Diagnostics is -1.10. Previous Next 2.4 News and Social Media Coverage News SentimentCo-Diagnostics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Co-Diagnostics this week, compared to 1 article on an average week.Search Interest3 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Co-Diagnostics Stock (NASDAQ:CODX)Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More CODX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CODX Stock News HeadlinesApril 26, 2024 | americanbankingnews.comHead to Head Review: Co-Diagnostics (NASDAQ:CODX) and PolyPid (NASDAQ:PYPD)April 25, 2024 | prnewswire.comCo-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and WebcastApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 24, 2024 | prnewswire.comCo-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in TaiwanApril 17, 2024 | morningstar.comCo-Diagnostics Inc Registered ShsApril 12, 2024 | prnewswire.comCo-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting EventApril 4, 2024 | prnewswire.comCo-Diagnostics, Inc. Appoints New President and Other C-Level PositionsMarch 21, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote AddressApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 18, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, EnglandMarch 17, 2024 | uk.finance.yahoo.comA Look At The Intrinsic Value Of Edel SE & Co. KGaA (ETR:EDL)March 17, 2024 | uk.news.yahoo.comHolby City star Rosie Marcel calls for Casualty not to kill off CharlieMarch 16, 2024 | finance.yahoo.comCo-Diagnostics Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comWe Think Co-Diagnostics (NASDAQ:CODX) Needs To Drive Business Growth CarefullyMarch 15, 2024 | finance.yahoo.comCo-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comQ4 2023 Co-Diagnostics Inc Earnings CallMarch 15, 2024 | markets.businessinsider.comMaintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA BoostMarch 15, 2024 | finance.yahoo.comCODX Mar 2024 1.500 callMarch 14, 2024 | investorplace.comCODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCo-Diagnostics: Q4 Earnings InsightsMarch 14, 2024 | prnewswire.comCo-Diagnostics, Inc. Reports Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comEarnings Preview: Co-DiagnosticsMarch 13, 2024 | markets.businessinsider.comHere's what to expect from Co-Diagnostics's earningsMarch 7, 2024 | finance.yahoo.comCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR TestFebruary 29, 2024 | morningstar.comCo-Diagnostics Inc Registered Shs CODXFebruary 29, 2024 | prnewswire.comCo-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and WebcastFebruary 15, 2024 | seekingalpha.comCODX Co-Diagnostics, Inc.See More Headlines Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CODX CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+117.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-518.69% Pretax Margin-559.47% Return on Equity-35.37% Return on Assets-32.58% Debt Debt-to-Equity RatioN/A Current Ratio10.81 Quick Ratio10.52 Sales & Book Value Annual Sales$6.81 million Price / Sales5.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.41Miscellaneous Outstanding Shares31,260,000Free Float30,510,000Market Cap$35.95 million OptionableOptionable Beta-0.68 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Dwight H. Egan (Age 71)Chairman & CEO Comp: $415.75kMr. Brian L. Brown CPA (Age 48)CFO & Company Secretary Comp: $338.92kMr. Richard David Abbott (Age 52)President Dr. Brent C. Satterfield Ph.D. (Age 47)Co-Founder & Member of Scientific Advisory Board Comp: $237.5kMr. David NielsenChief Operating OfficerMr. Dan Bohrer CPAVice President of Finance & AccountingMr. Christopher ThurstonChief Technology OfficerDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMore ExecutivesKey CompetitorsLENSARNASDAQ:LNSRLucid DiagnosticsNASDAQ:LUCDModular MedicalNASDAQ:MODDSpectral AINASDAQ:MDAIiCADNASDAQ:ICADView All CompetitorsInstitutional OwnershipSMI Advisory Services LLCBought 20,590 shares on 4/15/2024Ownership: 0.122%View All Institutional Transactions CODX Stock Analysis - Frequently Asked Questions Should I buy or sell Co-Diagnostics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares. View CODX analyst ratings or view top-rated stocks. What is Co-Diagnostics' stock price target for 2024? 1 equities research analysts have issued 1 year price targets for Co-Diagnostics' stock. Their CODX share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 113.7% from the stock's current price. View analysts price targets for CODX or view top-rated stocks among Wall Street analysts. How have CODX shares performed in 2024? Co-Diagnostics' stock was trading at $1.33 at the beginning of the year. Since then, CODX shares have decreased by 12.0% and is now trading at $1.17. View the best growth stocks for 2024 here. Are investors shorting Co-Diagnostics? Co-Diagnostics saw a decline in short interest in April. As of April 15th, there was short interest totaling 453,000 shares, a decline of 8.8% from the March 31st total of 496,500 shares. Based on an average trading volume of 56,600 shares, the days-to-cover ratio is currently 8.0 days. View Co-Diagnostics' Short Interest. When is Co-Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CODX earnings forecast. How can I listen to Co-Diagnostics' earnings call? Co-Diagnostics will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.50) EPS for the quarter. The firm earned $3.56 million during the quarter, compared to the consensus estimate of $3.63 million. Co-Diagnostics had a negative net margin of 518.69% and a negative trailing twelve-month return on equity of 35.37%. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ). When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. Who are Co-Diagnostics' major shareholders? Co-Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SMI Advisory Services LLC (0.12%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson. View institutional ownership trends. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CODX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
